Nevertheless, MET primarily regulates PD-L1 via the MAPK and PI3K/AKT pathways rather than the NF-κB pathway in EGFR-TKI-resistant NSCLC cells and whether NF-κB is involved in the MAPK pathway’s regulation of PD-L1 requires further investigation (90). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.